BACKGROUND
there is a growing perception that the traditional approach for drug development has not been as effective as could be expected  <cit> . although investments by pharmaceutical companies have been growing continuously in the last decades, the number of newly approved drugs has not followed the same trend  <cit> . currently the main trend in drug design and development follows the target-based approach. the drug target is generally a single gene or gene product which has been clearly identified as having an action on the disease. disease treatment seeks to modulate this action without affecting other processes in the organism. however, many diseases are multifactorial, and the current approach fails to take such systemic aspects into account  <cit> . the complex interactions between numerous molecular processes and pathways involved in diseases imply that any treatment targeting a local element will create secondary effects on the entire system. the lack of an integrative investigation of drug action can lead to either positive or negative systemic effects being missed. in the first case, the treatment only provides limited and localized cure for the disease while failing to address large-scale causes. in the second case, new drugs are developed with harmful side effects that are only revealed at a late stage of clinical studies. this problem of drug attrition is a major concern for the pharmaceutical industry and an important source of financial costs. additional problems can be caused by side-effects resulting from combinations of several drugs, arising from unexpected interactions which were not revealed by local analysis.

to increase the productivity of drug development and the efficiency of new drugs, there is thus a strong need to move beyond the investigation of drug action from the point of view of direct targets only, and to take into account the full network of interactions connecting the targets with the rest of the system. drug development needs to be approached not only in terms of a molecular biology process, but also as a systems biology process  <cit> . this awareness has recently led to the completion of major studies revealing the large-scale interactions between drugs, drug targets and diseases from a network-based perspective  <cit> . however, these approaches did not unveil yet how specific drugs interact in biochemical systems, and new methods are needed to gain an integrated perspective of the mechanisms of drug action in complex systems.

to this aim, we here introduce a new view of drug-metabolism interactions based on the concept of metabolic drug scope. the concept of a scope was previously developed in metabolic networks  <cit> . it uses an expansion process based on the principle that, for any reaction to take place, all necessary substrates must be present and the products of these reactions may in turn be used by other reactions. starting from a set of seed compounds, reactions whose substrates are available in the seed set are iteratively added, resulting in the generation of a series of expanding networks. when no further reaction can be added, the final network obtained is defined as the scope of the seeds. the scope represents the set of all compounds that can in principle be synthesized from the seeds. the properties of scopes in metabolic networks have been described in great detail  <cit> . this concept was already proven valuable in revealing features of the evolution of metabolic systems, leading notably to demonstrating how the shift from anoxic to oxic environments transformed the architecture of metabolic networks and how the availability of oxygen allowed an increase in biological complexity  <cit> . recently, it was shown that features of scopes could also be linked to chemical structures and biological functions of the seeds  <cit> .

we here extend the scope paradigm to drug-metabolism interactions. many drugs target genes or gene products that are involved in metabolic functions. when a metabolic reaction is targeted by a drug, the concentrations of its substrates and products are affected as a result of drug action. other reactions which use the products of the initial reactions are in turn affected by these perturbations. by iterative expansion, the entire scope of the initial substrates and products can in principle be affected by the drug. basing on this principle, we thus introduce the concept of a metabolic drug scope defined by the following: the scope of a drug is the scope resulting from the expansion of a set of seed compounds containing the substrates and products of all metabolic reactions targeted by that drug.

the metabolic drug scope essentially represents the largest network of possible action of a drug in a metabolic system. in the following sections, we show how metabolic drug scopes reveal new features of the systemic modes of drug action through a detailed analysis of the scopes of  <dig> human approved drugs from the drugbank database  <cit>  having metabolic targets. as scopes depend on the topology of the metabolic network used in the expansion process, we analyzed the action of each drug in four different systems: a human vs. a reference metabolic network consisting of the union of all organisms, and for each of those a reversible vs. an irreversible topology. further details on the construction of metabolic drug scopes are provided in the methods section. our results show that the distribution of scopes is highly uneven and that they can be classified into different categories. some drugs have small scopes associated to localized action, while others have large scopes associated to potential widespread systemic action. these classes are relatively well conserved throughout the four systems. a network of metabolic drug scopes, where scopes are connected when their jaccard distance is smaller than a given threshold, confirms these characteristics, and a k-core decomposition algorithm reveals several highly connected central components as well as peripheral subgraphs. we subsequently analyzed the correlations between metabolic drug scopes and therapeutic properties of drugs, and show that therapies are not distributed uniformly but can often associated to specific groups of scopes, correlated to similar k-cores. metabolic drug scopes therefore offer a new avenue to analyze drug-metabolism interactions and may provide valuable assistance to the drug development and assessment process.

RESULTS
metabolic drug scopes are highly uneven
the first step in characterizing the properties of metabolic drug scopes consisted in analyzing the distribution of their sizes. in many cases multiple drugs have the same targets and these drugs automatically have the same scope. to avoid identical scopes to be counted several times, we beforehand selected a subset of scopes where only one representative of each group of identical scopes was kept, resulting in a group of  <dig> scopes which are all different. the distributions of sizes of these scopes are shown in figure  <dig> for each of the four metabolic networks.

histograms reveal a highly heterogeneous distribution. scope sizes are not distributed evenly, nor do they show any kind of regular distribution law. on the contrary, sizes are often concentrated around particular values: for example, in the reference reversible network there are  <dig> scopes of size comprised between  <dig> and  <dig>  the presence of such peaks can be attributed to particular metabolites. it is known that the inclusion of ubiquitous metabolites has a strong influence on the size of scopes  <cit> . the most frequent of them is atp, which together with water and oxygen generate a scope of  <dig> compounds. the previously mentioned peak is thus clearly attributable to the presence of atp. nevertheless, it is remarkable that scopes do not exhibit larger variations around peaks. this observation suggests that metabolic drug scopes can be separated into distinct and relatively homogeneous groups, where internal variations are small.

we analyzed the distribution of scope sizes with regard to the total number of targets of each drug, including non-metabolic targets, in the four metabolic networks . the distribution shows that there is no significant correlation between these two variables . this observation confirms that scopes are more dependent on the presence of particular metabolites than on the number of targets.

the frequencies of occurrence of chemical compounds and reactions in metabolic drug scopes are plotted in figures  <dig> and  <dig> respectively. these distributions are very irregular and do not follow any classical law either. peaks can be observed at some values, separated by intervals of zero frequency. such distributions can be explained by the fact that scopes tend to grow through the incorporation of groups of metabolites, ubiquitous metabolites bringing large numbers of other metabolites with them. the sharp peaks observed at some high values, particularly for the reference network, are a further indication that groups of very similar scopes exist. each of these peaks corresponds to a group of scopes containing many of the same compounds and reactions. it was thus desirable to use clustering methods to reveal such groups of drugs.

scopes reveal four main categories of systemic drug action
we clustered metabolic drug scopes using the jaccard distance as a measure of dissimilarity between scopes . in the reference reversible network, four clusters of metabolic drug scopes were obtained, whose main properties are listed in table  <dig>  in order to highlight the main features and differences between these clusters, we constructed the consensus scope of each cluster. the consensus scope is the set of compounds present in at least 50% of all scopes of a cluster . consensus scopes of the four clusters are plotted over a genome scale metabolic map in figure  <dig> 

clear differences can be observed between these four drug clusters. cluster i is composed of drugs whose scope is very small. these scopes only slightly differ from the minimal scope induced by water and oxygen alone. when only water and oxygen are used as seeds and cofactors are allowed, a minimal scope of  <dig> compounds is obtained. the average size of scopes in cluster i is  <dig>  and the size of their consensus scope is  <dig>  these scopes thus mainly consist of the minimal scope with the addition of a handful of other compounds. these additional compounds are isolated and poorly connected to the rest of the metabolic network, as they do not further increase the size of the scope. drugs belonging to cluster i are therefore only able to affect a limited and specific part the metabolic network. their action is not allowed to propagate beyond the intended target and should be mainly local.

cluster iii contains the same minimal component induced by water and oxygen, but additionally contains a larger component centered on arachidonic acid metabolism. this component, which can be seen at the left-hand side of the genome scale metabolic map , is absent from the three other clusters. interactions of certain drugs with arachidonate metabolism have long been known and this pathway is particularly important in anti-inflammatory treatments  <cit> .

clusters ii and iv on the contrary contain large scopes spreading through many parts of the metabolic network. drugs belonging to these clusters can therefore in principle affect a wide area of metabolism and potentially have widespread systemic effects. such dramatic increase in the size of scopes can be achieved by the inclusion of particular metabolites. for example, raymond and segr√®  <cit>  showed that the availability of oxygen leads to a major expansion of the size and complexity of metabolic systems. although oxygen and water where assumed to be always available in our analysis, similar increases can be achieved by the inclusion of other metabolites. the most important of them is atp, which explains the distinction between cluster ii and iv: atp is present in all scopes of cluster ii but absent from the scopes of cluster iv. it is worth noticing that atp does not have the largest scope of all metabolites though: this position is held by adenosine 5'-phosphosulfate  <cit> , which is only present in a small number of scopes of cluster ii . the size of a compound's scope alone is thus not a determining factor for its recurrent occurrence in metabolic drug scopes. pyruvate plays a major role too in separating different clusters, as it is present in clusters ii and iv, but absent from clusters i and iii.

drug categories are conserved in different networks
the scope construction process fundamentally depends on the topology of the underlying metabolic network. we therefore conducted the same analysis in four different networks: a reference network consisting of the union of all organisms vs. a human metabolic network, and in each of those a reversible vs. an irreversible topology . clustering of metabolic drug scopes in these other networks resulted in more clusters being found than in the reference reversible network . however, most of these new clusters are very small, containing only in a handful of drugs. they would fall into one of the four main clusters if the cutoff were increased. the detailed composition of clusters is provided for the four networks in additional file  <dig> 

the four main clusters are still present and exhibit similar characteristics as in the reference reversible network. although the average size of scopes is smaller in irreversible and human networks than in the reference reversible case , it is worth noticing that the consensus scopes of the four main clusters remain very similar to their reference reversible counterparts . overlaps between consensus scopes from different clusters were made apparent by venn diagrams . groups consisting of large  and small scopes  are clearly distinguishable in the reference reversible network. in the reference irreversible network, this pattern is well conserved despite additional small clusters appearing. in human networks, more complex overlapping patterns emerge but two groups of large scopes are still present.

more significantly, the drug composition of the four main clusters is well conserved throughout the different networks . cluster iii is even 100% conserved in all four networks. the only significant difference appears with cluster iv, which is less conserved in the human irreversible network. the latter network is the less densely connected of all four, therefore emphasizing the dependence of metabolic drug scopes on local targets and leading to a higher scattering of scopes. table  <dig> shows that this network has a large number of very small clusters, making it more difficult to identify large groups of drugs with common properties as a result. on the other side, this network is the most appropriate when it comes to identifying highly specific drug-metabolism interactions, as scopes tend to be more restricted to the immediate neighborhood of drug targets.

metabolic drug scopes are correlated to therapeutic properties
as metabolic drug scopes are related to features of the systemic modes of drug action, a fundamental question was to determine whether the properties of metabolic drug scopes could be linked to therapeutic properties of the drugs themselves. we consequently analyzed the distribution of therapeutic properties, defined by level  <dig> tags of the atc classification , in the four main groups of drugs identified by clustering of their scopes. as shown in figure  <dig>  the repartition of therapies is not uniform in the four groups. while clusters ii and iv show relatively similar compositions in therapies, they together strongly differ from clusters i and iii. 55% of drugs in cluster iii belong to the musculo-skeletal system  category, and 77% of all class m drugs belong to cluster iii. the enrichment of class m in cluster iii is statistically highly significant . cluster i is dominated by antiinfectives  and sensory organs drugs ; it contains half of all blood related drugs  and three quarters of hormonal preparations . clusters ii on the contrary is dominated by cardiovascular drugs , this class is almost absent from cluster i and iii.

the fact that clusters ii and iv show more similarities than the other clusters must be put into relation with the fact that these two clusters correspond to large scopes, while clusters i and iii correspond to small specific scopes. therefore, there appears to be a relationship between the composition and extent of a metabolic drug scope and its therapeutic properties. this observation reinforces the potential role of scopes as an indicator of drug action and effects in a systems-wide context.

a complementary analysis of the relationships between metabolic drug scopes and therapies was realized by constructing a network of scopes . complex interwoven interactions can be analyzed in networks by identifying the cohesive building blocks of the system. cohesive subgraphs are sets of nodes with high density of edges in their network neighborhood. we applied an iterative decomposition method to uncover k-core subnetworks, defined as the largest subgraphs where every node has at least degree k. figure  <dig> shows the decomposition of a network of metabolic drug scopes, for a threshold of  <dig>  in the jaccard distance between scopes and in the human irreversible case. each colored node represents a different core partition. highly connected drugs are located in innermost cores where overlapping with complete therapy graphs is more evident. the overlapping of therapy cliques with k-core subgraphs confirms links between the composition of scopes and the effects of drugs.

discussion
it is a widely accepted fact that new approaches are needed to facilitate and increase the quality of the drug target identification and drug development processes. high levels of investment by pharmaceutical companies in recent years have not been followed by a corresponding increase in discovery and commercialization of new drugs, and the traditional reductionist approach of drug development is seen as a possible cause for this lack of success. many diseases are multifactorial and can not be handled by targeting only isolated molecules, but systemic aspects need to be taken into account. the toxicity and harmful side-effects of some drugs can also be accounted to by a failure of considering drug action in an integrated and systemic way. when a molecular target is perturbed by a drug, effects are not limited to that target but potentially extent to the whole interaction network connected to it. it therefore becomes more and more necessary to study drug action with a systems biology perspective, and important efforts are needed to construct and characterize the interaction networks connecting drug targets to all components of a biological system.

the metabolic network is one of these interaction networks, and metabolic drug scopes provide a straightforward and efficient tool to construct them and to analyze their properties. we have shown that metabolic drug scopes can vary greatly in size and distribution. when a drug has a small scope, its action is necessarily restricted to a small set of reactions and compounds. whether this feature should be considered as enviable or not is open to discussion, and most certainly depends on the context. when a disease is due to the malfunction of a specific process or the lack of a specific metabolic compound, a small scope would a priori be preferable, since it guarantees that no harmful side-effects are induced by the drug. large scopes are more difficult to assess: on the one side, a drug with a large scope is potentially more efficient in combating a multifactorial disease, as its effects can extend far beyond the immediate targets. on the other side, because it is difficult so far to quantify such large-scale effects, it cannot be excluded that they might include negative consequences for the organism. a wishful goal for the future should therefore involve moving beyond this type of qualitative view of drug-metabolism interactions towards a more quantitative view. for example, being able to predict which reactions and compounds of the metabolic drug scope are enhanced or repressed by the drug's action could lead to a whole new level of knowledge.

it is also remarkable that correlations can be observed between metabolic drug scopes and therapeutic properties of drugs. this observation strengthens the relevance of metabolic drug scopes in studying a drug's action and effects in a systems-wide context. as they discriminate the networks of action of different drugs, scopes also offer discrimination between the consequences of these actions. whether this finding can be turned into a predictive tool, i.e. to determine scopes and drug targets with the aim of obtaining a desired effect, remains open to investigation but certainly represents a promising perspective.

CONCLUSIONS
metabolic drug scopes provide a new perspective on interactions between drugs and metabolic systems going beyond more traditional network-based approaches. this analysis constitutes a first step in the integration between drug-target interaction networks on the one side, and stoichiometric interactions in metabolic systems on the other. in the future, such approaches will have to be extended toward quantitative modeling, with the aim of achieving a precise understanding of how drugs interact with living systems. this knowledge will in turn enable us to improve the drug development process and create more efficient therapies based on optimized combinations of multiple drugs.

